ClinicaliQ Trial Snapshot
- A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight — Active Not Recruiting • Phase III • Diabetes / Metabolic • NCT06388187.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant. Conditions: Obesity Interventions: Cagrilintide, Semaglutide, Placebo Lead Sponsor: Novo Nordisk A/S Planned Enrollment: 300 participants